Health Economics›Colorectal cancer›Maintenance after first-line therapy

Maintenance after first-line therapy

Colorectal cancer · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Bevacizumab monotherapy Variant #08	—	R 57 246	21d	4.9 mo	—	8	R 457 971 PFS proxy	—
Bevacizumab monotherapy Variant #08	RAS	R 57 246	21d	4.9 mo	—	8	R 457 971 PFS proxy	—
Capecitabine and Bevacizumab Variant #01	—	R 29 610	21d	5.6 mo	—	9	R 266 486 PFS proxy	3
Cetuximab monotherapy Variant #04	RAS	R 29 164	7d	—	~8.1 mo	—	—	3
FULV and Bevacizumab (L-Leucovorin) Variant #01 Partial	—	R 10 256	14d	~9.4 mo	—	~21	~R 215 377 PFS proxy · indirect	1
Fluorouracil and Bevacizumab Variant #01	—	R 10 201	14d	5.6 mo	—	13	R 132 614 PFS proxy	2
Capecitabine monotherapy Variant #17	—	R 2 219	21d	5.2 mo	—	8	R 17 755 PFS proxy	2
Observation Partial	—	—	—	3.4 mo	—	—	—	1
S-1 monotherapy Variant #01 Partial	—	—	21d	~1.7 mo	~10.5 mo	~3	—	13

9 of 9 regimens shown